Catechol-O-methyltransferase (COMT) polymorphisms predict treatment response in electroconvulsive therapy

Pharmacogenomics Journal

Volumn 8, Issue 2, 2008, Pages 113-116

  Anttila, Sami ^a,b   Huuhka, Kaija ^a,b   Huuhka, Martti ^a,b   Illi, Ari ^a,c   Rontu, Riikka ^a,b   Leinonen, Esa ^a,b   Lehtimäki, Terho ^a,b  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c KANTA HÄME CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CATECHOL METHYLTRANSFERASE; HYPNOTIC AGENT; NEUROLEPTIC AGENT;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; ELECTROCONVULSIVE THERAPY; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREFRONTAL CORTEX; PRIORITY JOURNAL;

ADULT; AGED; CATECHOL O-METHYLTRANSFERASE; DEPRESSIVE DISORDER, MAJOR; ELECTROCONVULSIVE THERAPY; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE FREQUENCY; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 40949114645     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500468     Document Type: Article

References (18)

1. UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: A systematic review and meta-analysis. Lancet 2003; 361: 799-808.
2. Millan MJ. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006; 110 135-370.
3. Kapur S, Mann JJ. Role of the dopaminergic system in depression. Biol Psychiatry 1992; 32: 1-17.
4. Yoshida K, Higuchi H, Kamata M, Yoshimoto M, Shimizu T, Hishikawa Y. Single and repeated electroconvulsive shocks activate dopaminergic and 5-hydroxytryptaminergic neurotransmission in the frontal cortex of rats. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 435-444.
5. Ishihara K, Sasa M. Methanism underlying the therapeutic effects of electroconvulsive therapy (ECT) on depression. Jpn J Pharmacol 1999; 80: 185-189.
6. Lammers CH, Diaz J, Schwartz JC, Sokoloff P. Selective increase of dopamine D3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry 2000; 5: 378-388.
7. Henry ME, Schmidt ME, Matochik JA, Stoddard EP, Potter WZ. The effects of ECT on brain glucose: A pilot FDG PET study. J ECT 2001; 17 33-40.
8. Andrade C, Srinivasamurthy GM, Vishwasenani A, Prakash GS, Srihari BS Chandra JS. High but not low ECS stimulus intensity augments apomorphine-stimulated dopamine postsynaptic receptor functioning in rats. J ECT 2002; 18: 80-83.
9. Lachman HM, Papolos DF, Saito T, Yu YM, Szurelanski CL, Weinshilbourn RM. Human catechol-O-methyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996; 6: 243-250.
10. Grover S, Mattoo SK, Gupta N. Theories on mechanism of action of electroconvulsive therapy. German J Psychiatry 2005; 8: 70-84.
11. Szegedi A, Rujescu D, Tadic A, Muller MJ, Kohnen R, Stassen HH et al. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J 2005; 5: 49-53.
12. Arias B, Serretti A, Lorenzi C, Gasto C, Catalan R, Fananas L. Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. J Affect Disord 2006; 90:251-256.
13. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 1998; 95:9991-9996.
14. Fisman M, Rabheru K, Hegele RA, Sharma V, Fisman D, Doering M et al. Apolipoprotein E polymorphism and response to electroconvulsive therapy. J ECT 2001; 17: 11-14.
15. Huuhka M, Anttila S, Leinonen E, Huuhka K, Rontu R, Mattila KM et al. The apolipoprotein E polymorphism is not associated with response to electroconvulsive therapy in major depressive disorder. J ECT 2005; 21: 7-11
16. Huuhka K, Anttila S, Huuhka M, Leinonen E, Rontu R, Mattila KM et al. Brain-derived neurotrophic factor (BDNF) polymorphisms G196A and C270T are not associated with the response to electroconvulsive therapy in major depressive disorder. Eur Arch Psychiatry Clin Neurosci 2007; 257: 31-35.
17. Anttila S, Huuhka K, Huuhka M, Rontu R, Mattila KM, Leinonen E et al. Interaction between TPH1 and GNB3 genotypes and electroconvulsive therapy in major depression. J Neural Transm 2007; 114: 461-468.
18. Livak KJ. Allelic discrimination using fluorogenic probes and the 5′ nuclease assay. Genet Anal 1999; 14: 143-149.